Status:
COMPLETED
Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
Lead Sponsor:
Ottawa Fertility Centre
Collaborating Sponsors:
EMD Serono
Conditions:
Infertility
Poor Ovarian Reserve
Eligibility:
FEMALE
18-41 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if growth hormone given 4 weeks before as well as during a cycle of in vitro fertilization will improve outcomes in women who have had previous failure with I...
Detailed Description
Growth hormone (GH; Saizen®) is indicated for the treatment of growth hormone deficiency in both children and adults, as well as for Turner's Syndrome, chronic renal failure, and children born short f...
Eligibility Criteria
Inclusion
- less than 42 years of age
- previous IVF cycle with high doses of gonadotropins (defined as greater than or equal to 400 IU/day)
- produced less than 6 follicles greater than or equal to 15mm
Exclusion
- any known contraindications to the approved fertility drugs as per the Canadian Product Monographs
- any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment), or are at risk for gestational diabetes
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01204840
Start Date
September 1 2010
End Date
May 1 2015
Last Update
July 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Fertililty Centre
Ottawa, Ontario, Canada, K2C 3V4